

**DEVELOPMENT OF HSPX VACCINE AGAINST
LATENT TUBERCULOSIS USING ADJUVANT-
DEPENDENT T-HELPER ALTERNATING
PEPTIDE STRATEGY**

LEW MIN HAN

UNIVERSITI SAINS MALAYSIA

2020

**DEVELOPMENT OF HSPX VACCINE AGAINST
LATENT TUBERCULOSIS USING ADJUVANT-
DEPENDENT T-HELPER ALTERNATING
PEPTIDE STRATEGY**

by/oleh

LEW MIN HAN

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

November 2020

ACKNOWLEDGEMENT

First and foremost, I would like to express my deepest gratitude to my main supervisor, Dr. Tye Gee Jun, for guiding me throughout my journey towards pursuing a Ph. D. degree in Molecular Medicine. He is a highly effective, optimistic and authentic supervisor, who has truly inspired me in many ways. Thank you for your patience and efforts to encourage me in gaining insights into the intricate network of immune system and vaccine development. He has also taught me skills to acquire independent thinking and to solve experimental problem critically. It was truly a great honour to work with him as a team player. Besides, I am thankful to my co-supervisor, Assoc. Prof. Dr. Lim Theam Soon, for his kindness to share his invaluable knowledge with me during my postgraduate study. Special thanks to Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia (USM), for providing us the necessary facilities and equipment as required for the conduct of our research work. I thank Animal Research and Service Centre (ARASC) for supplying experimental mice for my *in vivo* study, and thanks to Dr. Isma Suzyta Binti Ismail and Ms. Adilah Binti Abdul Khalil for their kind assistance. I also want to say thanks to Malaysian Institute of Pharmaceuticals and Nutraceuticals (Ipharm) for giving me the opportunity to assess their flow cytometry facilities for immunophenotyping assays. Furthermore, I thank Mybrain Kementerian Pengajian Tinggi (KPT) scholarship, Fundamental Research Grant Scheme (FRGS, 203/CIPPM/6711380) and Higher Institution Centre of Excellence (HiCoE, 311/CIPPM/4401005) grant for their financial support to my research work. I am very much thankful to my parents for their love and sacrifices in supporting me to pursue a higher level of education. I also want to dedicate my gratitude to my siblings for their kindness and motivations. I would not have

reached this far without your understanding, acceptance and continuous support along this long journey. I would like to thank my colleagues, Lee Shin Yong, Sylvia Annabel Dass, Chin Ding Sheng, Jacqueline Mark Kar Kei, Matthew Wong Tze Jian, Liew HuaQiang and Ahmad Ismail Abdo, for their friendship and motivation throughout my research study. It was my pleasure to work with all of you as a team. Besides, I also like to express my thanks to all my friends and staffs at INFORMM. Thank you for participating in this part of my life, our friendship is truly meaningful to me. Lastly, I would like to send my thanks anyone of you who have been giving me support upon the completion of my postgraduate study.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS.....	iv
LIST OF TABLES	xiv
LIST OF FIGURES	xv
LIST OF SYMBOLS	xix
LIST OF ABBREVIATIONS	xxi
LIST OF APPENDICES	xxxi
ABSTRAK	xxxii
ABSTRACT	xxxiv
CHAPTER 1 INTRODUCTION.....	1
1.1 The immune system	1
1.1.1 Innate immunity	2
1.1.2 Adaptive immunity	3
1.1.3 Crosstalk between innate and adaptive immunity.....	5
1.2 Humoral immunity	5
1.2.1 Antibody-mediated immune response	5
1.1.1 Activation of B-cells by CD4 T-cell help	8
1.3 T-cells and its cellular development.....	9
1.3.1 Colonisation of progenitor T-cells	9
1.3.2 Maturation of T-cells in thymic environment	10
1.3.2(a) Double negative (DN) phase	12
1.3.2(b) Double positive (DP) phase	12
1.3.2(c) Single positive phase (SP) phase	13
1.4 T-cell activation and differentiation	13

1.4.1	Signal 1: Engagement of T-cell receptor (TCR).....	15
1.4.2	Signal 2: Co-stimulatory signaling	17
1.4.3	Signal 3: Triggering of inflammatory cytokines.....	19
1.5	CD4 ⁺ T-helper cells (Th).....	19
1.5.1	Th1 cells.....	21
1.5.2	Th2 cells.....	23
1.5.3	Th17 cells.....	25
1.6	CD8 ⁺ T-helper cells (Tc).....	26
1.6.1	Activation of cytotoxic T-lymphocytes	27
1.6.2	Destruction of target cells	27
	1.6.2(a) Granule exocytosis pathway	28
	1.6.3(b) <i>Fas</i> signalling pathway.....	29
	1.6.3(c) Secretion of cytotoxic cytokines	29
1.7	Immunological memory of T-cells.....	30
1.7.1	Central memory T-cells (Tcm)	31
1.7.2	Effector memory T-cells (Tem)	32
1.7.3	Activation and differentiation of memory T-cells	32
1.7.4	Lifespan of memory T-cells.....	33
1.8	Homeostasis of T-cell response.....	34
1.8.1	Homeostatic control of naïve and memory T-cells.....	35
1.8.2	Immunosuppression by regulatory T-cell (Treg).....	36
	1.8.2(a) Inhibition through anti-inflammatory cytokine production.....	38
	1.8.2(b) Cell lysis by granzyme and perforins	39
	1.8.2(c) Metabolic disruption	39
	1.8.2(d) Interaction with dendritic cells	40
1.9	T-cell dysfunction	40

1.9.1	Senescence of T-cells.....	41
1.9.2	Exhaustion of T-cells	42
1.10	<i>Mycobacterium tuberculosis</i>	42
1.10.1	Pathogenesis of <i>Mycobacterium tuberculosis</i> infection.....	43
1.10.2	T-cell immunity against tuberculosis infection.....	45
	1.10.2(a) MHC presentation of mycobacterial peptides	47
	1.10.2(b) CD4 ⁺ T-cell response	47
	1.10.2(c) CD8 ⁺ T-cell response	48
1.11	Problem statement: Issues and challenges of BCG vaccine.....	49
1.11.1	Reduced immunogenicity in adults and the elderly	50
1.11.2	Varying efficacy of BCG vaccine	50
1.12	Vaccine development strategies against <i>M. tuberculosis</i>	51
1.12.1	Administration strategies of TB vaccines	52
1.12.2	Live bacteria as priming vaccine	53
1.12.3	Subunit vaccine as boosting vaccine.....	54
1.12.4	Therapeutic vaccines.....	55
1.12.5	Combined molecular adjuvant (CASAC) as vaccine delivery system.....	55
1.13	Strategy approach and rationale of study	57
1.13.1	Heat-shock tuberculosis antigen (HspX16.3)	58
	1.13.1(a) HspX antigen as a subunit vaccine candidate.....	58
	1.13.1(b) Induction of cytotoxic CD8 ⁺ T-cell response against latency-associated <i>M. tuberculosis</i>	60
1.13.2	Alternating T-helper peptide vaccination	62
1.14	Significance of study	64
1.15	Objectives of research	65

CHAPTER 2	MATERIALS AND METHODS	66
2.1	Rational design of the experiment	66
2.2	Materials	68
2.2.1	Biological materials	68
2.2.2	Chemicals, reagents and commercial kits	68
2.2.3	Antibodies	70
2.2.4	Cytokines and immunostimulants	70
2.2.5	Equipment, apparatus and consumables	71
	(a) Equipment	71
	(b) Apparatus	72
	(c) Consumables	72
2.2.6	Computational software	73
2.3	Methodology	74
2.3.1	Production of recombinant HspX tuberculosis antigen	74
	2.3.1(a) Construction and cloning of codon-optimised gene in pRSET-BH6 expression system	74
	2.3.1(b) Polymerase chain reaction (PCR)	75
	2.3.1(c) Restriction enzyme digestion	77
	2.3.1(d) Growth curve of <i>Escherichia coli</i> carrying HspX gene (HspX/BL21)	77
	2.3.1(e) Expression study of 6xHis-rHspX protein in <i>E. coli</i>	78
	2.3.1(f) Nickel-nitrilotriacetic acid (Ni-NTA) purification	78
2.3.2	Proteomic analysis	79
	2.3.2(a) Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)	79
	2.3.2(b) Western Blot detection	81
	2.3.2(c) Bradford assay for protein quantification	82

	2.3.2(d) Mass spectrometry (MALDI-TOF/TOF) analysis	83
2.3.3	<i>In silico</i> computational analysis of MHC-restricted peptides	83
2.3.4	Generation of synthetic MHC-peptides	84
2.3.5	Vaccine and adjuvant preparation.....	85
	2.3.5(a) CASAC adjuvant preparation.....	85
	2.3.5(b) Priming regimen.....	86
	2.3.5(c) Recombinant HspX vaccine	86
	2.3.5(d) MHC-I and II-restricted peptide vaccines.....	86
	2.3.5(e) Challenge dose using MHC-I peptide	88
2.3.6	<i>In vivo</i> immunisation of C57BL/6 mice.....	88
	2.2.6(a) Animals.....	88
	2.2.6(b) Administration of vaccines in mice	88
	2.2.6(c) Immunogenicity testing of rHspX protein.....	90
	2.2.6(d) Alternating MHC-peptide vaccination.....	92
2.3.7	Cell counting and viability test	94
2.3.8	Biological sample preparation from mouse	95
	2.3.8(a) Whole blood isolation	95
	2.3.8(b) Mouse sera	95
	2.3.8(c) Mouse peripheral mononuclear cells (PBMC)	96
	2.3.8(d) Isolation of mouse splenocytes	96
2.3.9	Detection of antigen-specific IgG antibody response	97
	2.3.9(a) Immunoglobulin (Ig) ELISA.....	97
	2.3.9(b) Monoclonal antibody (mAb) ELISA	98
2.3.10	Flow cytometry analysis	98
	2.3.10(a) Surface staining of biological samples.....	99
	2.3.10(b) Calibration of FACS instruments.....	100
	2.3.10(c) Compensation of 6-color fluorochromes.....	100

2.3.10(d)	Assay acquisition and analysis.....	101
2.3.10(e)	Daily cleaning procedures	101
2.3.11	Immunophenotyping of distinct T-cell population	102
2.3.11(a)	Light scattering analysis.....	103
2.3.11(b)	Antigen-specific memory CD8 ⁺ T-cell population	104
2.3.11(c)	Mouse regulatory T-cells.....	106
2.3.11(d)	Senescence and exhaustion of T-cell population	107
2.3.12	<i>In vivo</i> cytotoxic T-lymphocyte (CTL) analysis	109
2.3.12(a)	Peptide-loading of MHC-I restricted peptide.....	109
2.3.12(b)	CFSE staining of peptide-pulsed cells	109
2.3.12(c)	Adoptive transfer by intravenous (IV) injection	110
2.3.12(d)	Flow cytometry analysis of CFSE ⁺ and CFSE ⁻ population	110
2.3.13	T-cell cytokine profiling	112
2.3.13(a)	<i>In vitro</i> stimulation of mouse splenocytes.....	112
2.3.13(b)	Cytokine ELISA.....	112
2.3.13(c)	Intracellular cytokine analysis by flow cytometry	113
2.3.14	Statistical analysis	115
CHAPTER 3	RESULTS	116
3.1	Production of recombinant HspX protein in <i>Escherichia coli</i>	116
3.1.1	Codon-optimised HspX gene in pRSET-BH6 expression vector	116
3.1.2	Production of recombinant HspX protein in <i>Escherichia coli</i>	121
3.1.2(a)	Growth curve analysis of HspX/BL21 clone	121
3.1.2(b)	Expression of HspX gene in <i>Escherichia coli</i>	122
3.1.3	Mass spectrometry validation of recombinant HspX protein	124
3.1.4	Downstream purification of histidine-tagged recombinant HspX protein	125

3.2	Monoclonal antibody detection of rHspX protein.....	127
3.3	Immunogenicity of recombinant HspX protein.....	128
3.3.1	Humoral immune response against rHspX protein	128
3.3.1(a)	HspX-specific IgG ₁ antibody	128
3.3.1(b)	HspX-specific IgG _{2a} antibody	131
3.3.2	Cell-mediated immune response against rHspX protein.....	133
3.3.2(a)	Memory CD8 ⁺ T-cell response.....	133
3.3.2(b)	Antigen-specific CD8 ⁺ T-cell response	136
3.3.2(c)	Cytokine secretion.....	138
3.4	Prediction of MHC class I and II restricted peptides	140
3.5	CD8 ⁺ T-lymphocyte response induced by peptide vaccination	141
3.5.1	Antigen-specific CD8 ⁺ T-cell response.	142
3.5.1(a)	Time-course analysis of HspX-specific CD8 ⁺ T-cell response	142
3.5.1(b)	Challenge of MHC-I restricted peptides	142
3.5.1(c)	Th1 cytokine analysis.....	145
3.5.2	Memory CD8 ⁺ T-cell response elicited by MHC-I and -II peptides	147
3.5.2(a)	Central memory T-cell (Tcm)	147
3.5.2(b)	Effector memory T-cell (Tem)	148
3.6	Regulatory T-cell (Treg) population	150
3.7	Cytokine secretion by polyfunctional CD4 ⁺ T-cells	151
3.7.1	Th1-mediated cytokines.....	152
3.7.2	Th1, Th2 and Th17 cytokines.	153
3.8	Senescence and exhaustion of CD8 ⁺ T-cell response	154
3.8.1	KLRG1 ⁺ CD8 ⁺ T-cell response.....	155
3.8.2	PD1 ⁺ CD8 ⁺ T-cell response	157

3.8.3	LAG3 ⁺ CD8 ⁺ T-cell response	158
3.8.4	CTLA-4 ⁺ CD8 ⁺ T-cell response.....	160
3.9	Cytotoxic T-lymphocyte (CTL) activity upon peptide vaccination	161
CHAPTER 4 DISCUSSION		165
4.1	Production of recombinant HspX antigen in bacterial host	166
4.1.1	Recombinant HspX protein was highly expressed in <i>Escherichia coli</i>	166
4.1.2	Isolation of histidine-tagged rHspX protein.....	168
4.1.3	Recombinant HspX protein resembled its native counterparts	170
4.2	Enhancement of HspX-mediated immunity by CASAC adjuvant.....	172
4.2.1	Generation of humoral immunity against HspX antigen	174
	4.2.1(a) Increased HspX-specific IgG ₁ and IgG _{2a} production by CASAC adjuvant	174
	4.2.1(b) Maintenance of a mixed Th1/Th2 response by CASAC adjuvant.....	176
4.2.2	CASAC adjuvant enhanced CD8 ⁺ T-cell immunity against HspX antigen	178
	4.2.2(a) Increased antigen-specific CD8 ⁺ T-cell population	178
	4.2.2(b) Maintenance of memory CD8 ⁺ T-cell response by CASAC adjuvant	180
4.2.3	CASAC adjuvant potentiated inflammatory cytokine secretion upon HspX antigen	181
	4.2.3(a) IFN- γ , TNF- α and IL-10 secretion	184
	4.2.3(b) IL-12/IL-23p40 secretion	185
	4.2.3(c) IL-17A secretion	186
4.3	Fundamentals of MHC-based peptide vaccination design.....	187

4.4	Alternating peptide vaccination improved CD8 ⁺ T-cell immunity against HspX antigen.....	190
4.4.1	Prediction of MHC-restricted peptides	190
4.4.2	Enhanced stimulation of antigen-specific CD8 ⁺ T-cell population	191
4.4.3	Enhanced Th1 cytokine secretion.	193
4.5	Maintenance of immunological memory against HspX antigen.....	194
4.5.1	Central memory CD8 ⁺ T-cells.	196
4.5.2	Effector memory CD8 ⁺ T-cells	198
4.6	Regulation of CD8 ⁺ T-cell homeostasis by novel peptide vaccination.....	199
4.6.1	Maintenance of regulatory T-cell (Treg) population.	200
4.6.2	Regulation of cytokine milieu on CD8 ⁺ T-cell immunity.....	202
	4.2.6(a) Th1-mediated immunity	203
	4.2.6(b) Th1, Th2 and Th17 regulation	204
4.7	Fate of dysfunctional CD8 ⁺ T-cell	206
4.7.1	Senescence of antigen-specific CD8 ⁺ T-cells.	208
4.7.2	Exhaustion of antigen-specific CD8 ⁺ T-cells.....	209
	4.7.2(a) Programmed cell death protein (PD-1)	210
	4.7.2(b) Lymphocyte activated gene 3 (LAG-3)	211
	4.7.2(c) Cytotoxic T-lymphocyte-association protein 4 CTLA-4	212
4.8	Alternating peptide vaccination strategy enhanced cytotoxic T-lymphocyte (CTL) response against HspX antigen.....	213
4.9	Limitations of the study.....	217
4.10	Future studies	218

CHAPTER 5 CONCLUSION	221
REFERENCES.....	223
APPENDICES	
LIST OF PUBLICATIONS AND PRESENTATIONS	

LIST OF TABLES

	Page
Table 1.1 Current vaccination strategies against HspX antigen as candidate vaccine	61
Table 2.1 List of chemical	68
Table 2.2 List of molecular reagents	69
Table 2.3 List of cell culture media and reagents.....	69
Table 2.4 List of commercial kits	69
Table 2.5 List of antibodies	70
Table 2.6 List of cytokines and immnuostimulants.....	70
Table 2.7 List of equipment.....	71
Table 2.8 List of apparatus	72
Table 2.9 List of consumables	72
Table 2.10 List of computational software	73
Table 2.11 Nucleotide sequences of HspX-specific primers.....	75
Table 2.12 PCR condition for amplification of codon-optimised HspX gene	76
Table 2.13 The cycle program for PCR amplification	76
Table 2.14 Condition of restriction enzyme digestion	77
Table 2.15 SDS-PAGE polyacrylamide gel composition	80
Table 2.16 Chemical properties of synthetic MHC-I and MHC-II peptides	84
Table 2.17 HspX peptide vaccine preparation.....	87
Table 3.1 Prediction of MHC-I and MHC-II binding peptides	141

LIST OF FIGURES

	Page
Figure 1.1	The innate and adaptive immunity 1
Figure 1.2	Innate immune response against invading pathogen 3
Figure 1.3	The adaptive immune response 4
Figure 1.4	Antibody-mediated immune response 7
Figure 1.5	T-cell dependent B-cell activation..... 8
Figure 1.6	Maturation of T-cells in thymus 11
Figure 1.7	Three signals are required to activate antigen-specific T-cells 14
Figure 1.8	Maturation of immunological synapse of T-cells..... 16
Figure 1.9	Activation of CD4 ⁺ and CD8 ⁺ T-cells by antigen-presenting cells (APC) 18
Figure 1.10	Functional subsets of CD4 ⁺ T-helper cells (Th)..... 21
Figure 1.11	Th1 cells for pro-inflammatory response 23
Figure 1.12	Th2 cells for antibody productions and anti-inflammatory response 25
Figure 1.13	Th17 regulation on Th1 and Th2 activity..... 26
Figure 1.14	Cytotoxic CD8 T-cell activity 28
Figure 1.15	Central and effector memory T-cells..... 31
Figure 1.16	Homeostasis proliferation of T-cell response..... 35
Figure 1.17	Immunosuppressive effect of Treg cells..... 37
Figure 1.18	Senescence and Exhaustion of T-cells 41
Figure 1.19	Pathogenesis of <i>Mycobacterium tuberculosis</i> 45
Figure 1.20	Cellular immunity against <i>Mycobacterium tuberculosis</i> 46
Figure 1.21	Vaccine development pipeline against <i>Mycobacterium</i> <i>tuberculosis</i> 52

Figure 1.22	Enhancement of Th1-mediated response by CASAC adjuvant	56
Figure 1.23	Regulation of latent tuberculosis by 16 kDa HspX antigen	59
Figure 1.24	Rationale of alternating peptide vaccination	63
Figure 2.1	Flowchart of experimental design	67
Figure 2.2	Administration of vaccines in C57BL/6 mice.	89
Figure 2.3	Immunisation regimen used for evaluation of immune response against rHspX antigen in C57BL/6 mice (n = 5).....	91
Figure 2.4	MHC-peptide vaccination regimen in C57BL/6 mice.....	93
Figure 2.5	Measurement of cell viability, concentration and total cell number of mice PBMC and splenocytes	94
Figure 2.6	Identification of target population using fluorescence-minus-one (FMO) and unstained controls.....	102
Figure 2.7	Identification of T-lymphocytes in single cell suspension.	104
Figure 2.8	Gating of memory CD8 ⁺ T-cell population against HspX antigen. .	105
Figure 2.9	Gating strategy of FoxP3 ⁺ T-cell population.....	107
Figure 2.10	Gating of T-cell population with senescence and exhaustion	108
Figure 2.11	Gating strategy of CFSE ⁺ and CFSE ⁻ T-lymphocytes.....	111
Figure 2.12	Measurement of cell lysis percentage (%) upon HspX vaccination. .	112
Figure 3.1	Presence of HspX-gene in pRSET-BH6 vector determined by RE digestion and 1% agarose gel electrophoresis.....	118
Figure 3.2	Nucleotide alignment of codon-optimised HspX gene construct assembled to reference sequence.....	120
Figure 3.3	Growth curve of recombinant <i>Escherichia coli</i> (HspX/BL21) at 37°C.	122
Figure 3.4	Expression of histidine-tagged rHspX protein in BL21(DE3).....	123
Figure 3.5	Matrix-assisted laser desorption/ionisation-time of flight (MALDI-TOF) analysis of recombinant HspX protein.....	124

Figure 3.6	Ni-NTA purification of histidine-tagged rHspX protein under native condition	126
Figure 3.7	Monoclonal antibody detection of rHspX protein.....	127
Figure 3.8	Level of antigen-specific IgG ₁ antibody responses induced by HspX vaccination	130
Figure 3.9	Level of antigen-specific IgG _{2a} antibody responses stimulated by HspX vaccination	132
Figure 3.10	CD8 ⁺ T-cell population and memory subpopulation stimulated upon HspX vaccination.	135
Figure 3.11	Antigen-specific CD8 ⁺ T-cell response elicited upon challenge of HspX antigen.....	137
Figure 3.12	Cytokine secretion upon HspX vaccination supplemented with CASAC adjuvant.	139
Figure 3.13	MHC class I, II ^A and II ^B peptides were predicted based on 16 kDa heat-shock protein (Hsp16.3; α -crystallin).	140
Figure 3.14	Kinetics of antigen-specific CD8 ⁺ T-cell response in C57BL/6 mice.	144
Figure 3.15	Antigen-specific T-cell response during pre- and post- vaccination.....	144
Figure 3.16	Th1 cytokine secretion of HspX-specific CD8 ⁺ T-cell response upon antigenic stimulation	146
Figure 3.17	Central memory response (T _{cm}) of HspX-specific CD8 ⁺ T-cell population during challenge study.....	147
Figure 3.18	Central memory response (T _{cm}) of HspX-specific CD8 ⁺ T-cell Population during challenge study	149
Figure 3.19	Characterisation of CD4 ⁺ CD25 ⁺ FoxP3 ⁺ regulatory T-cells in total lymphocyte population	151

Figure 3.20	Th1 cytokines secreted by polyfunctional CD4 ⁺ T-cells.....	152
Figure 3.21	Th1, Th2 and Th17 cytokines secreted by polyfunctional CD4 ⁺ T-cells.....	154
Figure 3.22	KLRG1 ⁺ CD8 ⁺ T-lymphocytes upon challenge study	156
Figure 3.23	PD1 ⁺ CD8 ⁺ T-lymphocytes upon challenge study	157
Figure 3.24	LAG3 ⁺ CD8 ⁺ T-lymphocytes upon challenge study.	159
Figure 3.25	CTLA4 ⁺ CD8 ⁺ T-lymphocyte response upon challenge study	160
Figure 3.26	Cytotoxic T-lymphocyte (CTL) response in mice vaccinated with MHC-restricted peptides against HspX antigen	162
Figure 4.1	HspX-mediated humoral and cellular immunity was enhanced by incorporation of CASAC adjuvant	173
Figure 4.2	Secretion of inflammatory cytokines upon stimulation of HspX-expressing <i>M. tb</i> infection.....	183
Figure 4.3	MHC-restricted peptide vaccination strategies against HspX antigen	188
Figure 4.4	Kinetics of CD8 ⁺ T-cell population and its memory generation	195
Figure 4.5	Immune checkpoint involved in negative regulation of T-cell function.....	207
Figure 4.6	T-cell repertoires generated using MHC-I and MHC-II peptides against HspX antigen.....	216

LIST OF SYMBOLS

-	Low expression/downregulation
~	Approximately
°C	Celsius
+	High expression/upregulation
+	Plus/with addition of
=	Equal to
>	More than
±	More or less
≤	Less than or equal to
3'	End of DNA at carbon-3 position in its sugar-ring structure
5'	End of DNA at carbon-5 position in its sugar-ring structure
A _{405nm}	Absorbance observed at wavelength 405 nm
A _{595nm}	Absorbance observed at wavelength 595 nm
A _{600nm}	Absorbance observed at wavelength 600 nm
bp	Base pair
cm	Centrimeter
g	Gram
h	Hour
kbp	Kilo base pair
kDa	Kilo Dalton
L	Liter
M	Molar
mer	Number of peptide residues

mg	Miligram
mL	Milliliter
mm	Milimeter
mM	Milimolar
N	Normality
n	Sample size
ng	Nanogram
p	<i>p</i> -value
pg	Picogram
t	Time-point
™	Trademark
V	Volt
x	Multiply
xg	Times gravity
α	Alpha
β	Beta
γ	Gamma
δ	Delta
Δ	Mutational deletion
μg	Microgram
μL	Microliter
μm	Micrometer

LIST OF ABBREVIATIONS

2B4	Signaling lymphocyte activation molecule (SLAM) family receptor, CD244
2xYT	2 x Yeast Extract Tryptone
3D	Three-dimensional
6xHis	Six residues of histidine
A2AR	Adenosine A2A receptor
ABTS	2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid)
Acr1	Alpha-crystalline protein 1
Ad35	Adenovirus serotype 35 vector
Ad5	Adenovirus serotype 5 vector
ADCC	Antibody-dependent cellular cytotoxicity
Ag	Antigen
Ag85A	Antigen 85A complex
Ag85B	Antigen 85B complex
ANOVA	Analysis of variance
AP-1	Activator protein 1
APC	Antigen-presenting cell
APC	Allophycocyanin
APS	Ammonium Persulfate
ARASC	Animal Research and Service Centre
B7	Peripheral membrane protein CD80/CD86
BCG	Bacillus Calmette–Guérin
BCR	B-cell receptor

BD	Beckton Dickinson company
BLAST	Basic Local Alignment Search Tool
BSA	Bovine serum albumin
C57BL/6	C57 black 6 mice
cAMP	Cyclic adenosine monophosphate
CASAC	Combined adjuvant for synergistic activation of cellular immunity
CCL	CC chemokine ligand
CCR7	C-C chemokine receptor type 7
CD	Cluster of differentiation
CD40L	CD40 ligand, also called CD154
CD62L	L-selectin
cDNA	Complementary DNA
CFA	Complete Freund's Adjuvant
CFP-10	Culture filtrate protein 10
CFSE	Carboxyfluorescein succinimidyl ester
CFSE ^{high}	High CFSE signals, CFSE ⁺
CFSE ^{low}	Low CFSE signals, CFSE ⁻
CLPS	Common lymphoid progenitors
CO	Carbon monoxide
CO ₂	Carbon dioxide
CpG-ODN	Synthetic oligodeoxynucleotides containing unmethylated CpG motifs
CREB	cAMP response element-binding protein
cSMAC	Supra-molecular activation complex
cTECs	Cortical Thymic epithelial cells

CTL	Cytotoxic T-lymphocyte
CTLA-4	Cytotoxic T-lymphocyte-associated protein 4
CXCL2	Chemokine ligand 2
DAB	3,3'-diaminobenzidine
DCs	Dendritic cells
DDA	Dimethyldioctadecylammonium/trehalose 6,6,9-dibehenate
ddH ₂ O	Double distilled water
DMSO	Dimethyl sulfoxide
DN	Double negative
DNA	Deoxyribonucleic acid
DosR	Response regulator encoded by the <i>Rv3133c</i> gene of <i>M. tb</i> strain <i>H37Rv</i>
DosS	Sensory kinase encoded by <i>Rv3132c</i> gene of <i>M. tb</i> strain <i>H37Rv</i>
DosT	Sensory kinase encoded by <i>Rv2027c</i> gene of <i>M. tb</i> strain <i>H37Rv</i>
DOTAP	Dioleoyl-3-trimethylammonium propane
DP	Double positive
DPBS	Dulbecco's phosphate-buffered saline
DPG	Polyribocytidylic acid and gelatin
dSMAC	Distal area of pSMAC
dsRNA	Double stranded RNA
<i>E. coli</i>	<i>Escherichia coli</i>
EDTA	Ethylenediaminetetraacetic acid
ELISA	Enzyme-linked immunosorbent assay
EPI	Expanded Program on Immunisation
ESAT-6	Early secretory antigenic target protein 6

ESX-1	ESAT-6 secretion system 1
EsxS	ESAT-6-like protein
et al.	Et alia, and others
FACS	Fluorescence-activated cell sorting
<i>Fas</i>	Apoptosis antigen 1 (APO-1 or APT), also known as <i>FasR</i>
<i>FasL</i>	Ligand for <i>Fas</i> receptor
FBS	Fetal bovine serum
Fc	Fragment crystallizable region of antibody
FcγR	Fc gamma receptor
FITC	Fluorescein isothiocyanate dye
FMO	Fluorescence Minus One
Fmoc	Fluorenylmethoxycarbonyl protecting group
FoxP3	Forkhead box protein P3
FSC	Forward scatter
fTh	Follicular T helper cell
GATA-3	Zinc finger transcription factor
GM-CSF	Granulocyte-macrophage colony-stimulating factor
HEV	High endothelial venules
His	Histidine
HPLC	High Performance Liquid Chromatography
HRP	Horseradish peroxidase
HSC	Hematopoietic stem cells
HspX	Heat-shock protein α -crystallin tuberculosis antigen
HspX- pRSET	HspX-containing pRSET vector

i.d.	Intradermal injection
i.p.	Intraperitoneal injection
IDO	Indoleamine-pyrrole 2,3-dioxygenase
IEDB	Immune Epitope Database
IFN- γ	Interferon-gamma
Ig	Immunoglobulin
IgG ₁	Immunoglobulin isotype class 1
IgG _{2a}	Immunoglobulin isotype class 2a
Igk	Immunoglobulin kappa chain
IL	Interleukin
IL-2	Interleukin-2
IL-3	Interleukin-3
IL-12/23p40	Cytokine containing p40 subunit shared by IL-12 and IL-23
IL-15R	Interleukin-15 receptor
IL-2R	Interleukin-2 receptor
IL-7R	Interleukin-7 receptor
IPTG	Isopropyl β -D-1-thiogalactopyranoside
IRF-3	Interferon regulatory transcription factor 3
IRF-4	Interferon regulatory factor 4
IV	Intravenous injection
JAK-STAT	Janus Kinase/Signal Transducer and Activator of Transcription.
KIR	Human killer cell immunoglobulin-like receptors, CD158
KLRG-1	Killer cell lectin-like receptor subfamily G member 1
LAG-3	Lymphocyte-activation gene 3
LC	Liquid chromatography

Lck	Lymphocyte-specific protein tyrosine kinase
LT	Lymphotoxin
LTBI	Latent tuberculosis infection
Ltd	Limited company
<i>M. tb</i>	<i>Mycobacterium tuberculosis</i>
<i>M.</i> <i>tuberculosis</i>	<i>Mycobacterium tuberculosis</i>
MALDI- TOF	Matrix-assisted laser desorption/ionisation time of flight
MCP-1	Monocyte chemoattractant protein-1
MDA5	Melanoma differentiation-associated protein 5
MFI	Mean florescence intensity
MHC	Major histocompatibility complex
MHC-I	Major histocompatibility complex class one
MHC-II	Major histocompatibility complex class two
mIFN- γ	Mouse interferon gamma
MPL	Monophosphoryl lipid A
MPP	Multi-potential progenitor
MS	Mass spectrometry
MTBC	<i>Mycobacterium tuberculosis</i> complex
mTECs	Medullary thymic epithelial cells
MVA	Modified Vaccinia Ankara
MyD88	Myeloid differentiation primary response 88
n.s	Non-significant
NaH ₂ PO ₄	Sodium dihydrogen phosphate

NaHCO ₃	Sodium bicarbonate
NaOH	Sodium hydroxide
nark2	Probable nitrate/nitrite transporter
NC	Nitrocellulose membrane
NCBI	National Center for Biotechnology Information
NFAT	Nuclear factor of activated T-cell
NFkB	Nuclear Factor kappa-light-chain-enhancer of activated B cell
Ni-NTA	Nickel- nitrilotriacetic acid
NK	Natural killer cell
NKT	Natural killer T-cell
NLR	NOD-like receptor
NO	Nitric oxide
P1	Gated subpopulation at first level
P13K	Phosphoinositide 3-kinase
P13k/AKT	Phosphatidylinositol-3-Kinase/ Protein kinase B
P2	Gated subpopulation at second level
PAMPS	Pathogen-associated molecular patterns
PB	Pacific Blue
PBMC	Peripheral blood mononuclear cell
PBS	Phosphate-buffered saline
PBS-T	Phosphate-buffered saline with Tween detergent
PCR	Polymerase chain reaction
PD-1	Programmed cell death protein 1
PD-L1	Programmed death-ligand 1
PE	Phycoerythrin

PE/Cy7	Tandem fluorochrome that combines phycoerythrin and a cyanine
PerCP-Cy5.5	Tandem fluorochrome that combines Peridinin-Chlorophyll-Protein with a cyanine
pfkB	Phosphofructokinase B
pH	Potential of hydrogen
PKA	Protein kinase A
PLGA	Poly(lactic-co-glycolic acid)
PMA	Phorbol myristate acetate
pMHC	Peptide-bound MHC
pMHC-I	Peptide-bound MHC class I
pMHC-II	Peptide-bound MHC class II
PMT	Photomultiplier tube
PMTV	Photomultiplier tube voltage
Poly(I:C)	Polyinosinic:polycytidylic acid
PPE	Personal protective equipment
PQC	Performance quality control
PRR	Pattern recognition receptor
pSMAC	Peripheral ring surrounding the cSMAC
pTreg	Peripheral-derived Foxp3 ⁺ T-regulatory cell
Pty	Proprietary
RBC	Red blood cell
rBCG	Recombinant Bacillus Calmette–Guérin
RD-1	Region of difference 1
RE	Restriction enzyme
rHspX	Recombinant heat-shock α -crystallin tuberculosis antigen

RIG-1	Retinoic acid-inducible gene I
RLR	RIG-1 like receptor
RNA	Ribonucleic acid
ROR γ t	Retinoic acid-related orphan receptor gamma t
ROS	Reactive oxygen species
RP-HPLC	Reverse-phase High Performance Liquid Chromatography
RPMI-1640	Roswell Park Memorial Institute 1640 medium
SD	Standard deviation
SDS-PAGE	Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SEM	Standard error of mean
SIT	Signaling threshold-regulating transmembrane adapter protein
SOCS-1	Suppressor of cytokine signaling 1
SP	Single positive
SSC	Side scatter
STAT	Signal transducer and activator of transcription protein family
T/S	Tween-Squalene emulsion
TAP	Transporter associated with antigen processing
TB	Tuberculosis
T-bet	T-box transcription factor
Tc	Cytotoxic T-cell
Tcm	T-cell with central memory
TCR	T-cell receptor
TDB	Trehalose-6,6-dibehenate
TDR	Totally drug-resistant
Tem	T-cell with effector memory

TEMED	Tetramethylethylenediamine
TFH	T follicular helper cell
TGF- β	Tumor growth factor beta
Th	T-helper cell
Th0	Naive T-cell
Th1	T-helper type 1 cell
Th2	T-helper type 2 cell
TIM-3	T-cell immunoglobulin mucin-3
TLR	Toll-like receptor
TNFR-1	Tumor necrosis factor receptor 1
TNF- α	Tumor necrosis factor alpha
TNF- β	Tumor necrosis factor beta
Tr1	Type-1 regulatory T cell
Tr35	Regulatory T-cell that produces IL-35
Treg	Regulatory T-cell
Tris-HCl	Trisaminomethane hydrochloride
tTreg	Thymus-derived Foxp3 ⁺ T-regulatory cell
UK	United Kingdom
USA	United States of America
UV	Ultraviolet
UV-Vis	Ultraviolet–visible
WHO	World Health Organisation
XDR	Extensively drug-resistant
ZAP-70	Zeta-chain-associated protein kinase 70

LIST OF APPENDICES

APPENDIX A	FLOWCHART OF RESEARCH
APPENDIX B	MOLECULAR SEQUENCES OF NATIVE ALPHA-CRYSTALLIN HSPX ANTIGEN FROM <i>MYCOBACTERIUM TUBERCULOSIS</i>
APPENDIX C	CLONING OF CODON-OPTIMISED HSPX TUBERCULOSIS GENE INTO PRESET-BH6 EXPRESSION SYSTEM
APPENDIX D	VECTOR MAP OF PRSET-BH6 EXPRESSION SYSTEM
APPENDIX E	CONCENTRATION DETERMINATION OF RECOMBINANT HSPX PROTEIN
APPENDIX F	IN SILICO PREDICTION OF MHC-RESTRICTED PEPTIDES
APPENDIX G	CHEMICAL SYNTHESIS OF MHC-PEPTIDES
APPENDIX H	CHEMICAL SYNTHESIS OF MHC-PEPTIDES
APPENDIX I	CHEMICAL SYNTHESIS OF MHC-PEPTIDES
APPENDIX J	ANIMAL ETHICAL APPROVAL
APPENDIX K	STANDARD CURVE OF IGG1 AND IGG2A ANTIBODY DETECTION
APPENDIX L	FLUOROCHROME-CONJUGATED ANTIBODIES USED FOR FLOW CYTOMETRY
APPENDIX M	STANDARD CURVE FOR CYTOKINE ELISA DETECTION

**PEMBANGUNAN VAKSIN HSPX TERHADAP TUBERKULOSIS
LATEN DENGAN MENGGUNAKAN STRATEGI PEPTIDA PEMBANTU-T
BERSILIH GANTI BERSANDARKAN ADJUVAN**

ABSTRAK

Keimunan sel adalah satu faktor kritikal yang harus dipertimbangkan untuk pembangunan vaksin yang berkesan terhadap *Mycobacterium tuberculosis*. Hubungan antara CD4⁺ dan CD8⁺ limfosit T memainkan peranan yang penting untuk membunuh sel yang dijangkiti bacilli tuberkulosis. Berdasarkan prinsip tersebut, strategi vaksinasi peptida yang novel menggunakan peptida MHC untuk mengubah tindak balas CD8⁺ sel T terhadap protein α -kristal antigen tuberkulosis (HspX). Adjuvan vaksin (CASAC) telah dimasukkan ke dalam rejimen vaksin kami untuk merangsangkan sinergi imuniti terhadap antigen rekombinan HspX (rHspX). Data yang diperolehi menunjukkan rHspX dapat meningkatkan imunisasi yang khusus dalam tikus C57BL/6. Antibodi IgG₁ dan IgG_{2a} dan keimunan memori CD8⁺ sel T yang spesifik telah dirangsangkan oleh adjuvan vaksin CASAC. Rejimen vaksin tersebut menguatkan tahap rembesan IFN- γ dan TNF- α dengan penindasan IL-10. Ini menunjukkan bahawa keimunan sel yang dirangsangkan adalah dikawal oleh tindak balas Th1 dominan terhadap antigen HspX. Dalam kajian vaksinasi peptida, tikus C57BL/6 disuntikkan dengan protein rHspX dan vaksin subunit yang mengandungi peptida MHC-I/MHC-II dan adjuvan vaksin CASAC. Vaksinasi peptida bersilih ganti yang novel ini merangsangkan tahap tindak balas Th1 CD8⁺ sel T yang spesifik terhadap antigen HspX, seperti yang ditunjukkan dengan peningkatan rembesan IFN- γ dan IL-2. Ia juga menghasilkan reaksi ingatan berpusat (T_{cm}) dan efek (T_{em}) yang lebih kuat dibandingkan dengan kumpulan kajian lain. Ini membuktikan bahawa

ketahanan keimunan adalah mantap terhadap antigen HspX semasa kajian cabaran. Sel T regulator ($CD4^+$ $CD25^+$ dan $CD25^+$ FoxP3 $^+$) dan sel Th1, Th2 dan Th17 dengan pelbagai fungsi mengawal tindak balas imuniti secara berterusan semasa suntikan vaksinasi peptida bergantian, tanpa menunjukkan respon maklum balas yang negatif. Selanjutnya, vaksinasi peptida bergantian tidak merangsang penuaan dan keletihan $CD8^+$ sel T khusus terhadap HspX, seperti yang ditunjukkan dengan pengepresan yang rendah daripada KLRG1, PD1, LAG3, dan CTLA-4. Kajian kami menunjukkan bahawa vaksin peptida bergantian telah berjaya menghasilkan sel T pembunuh (CTL) yang menonjol terhadap antigen HspX, yang berkemampuan untuk menyingkir tisu yang dijangkiti dengan bakteria tuberkulosis laten. Sebagai kesimpulan, vaksinasi peptida bergantian yang unik ini berpotensi untuk mendorong tindak balas $CD8^+$ CTL yang berkesan terhadap antigen HspX. Ini adalah disebabkan manipulasi tindak balas $CD4^+$ sel-T dengan menggunakan peptida MHC-I dan MHC-II. Dengan penindasan keimunan yang minimum ini, vaksinasi peptida bergantian mungkin bermanfaat untuk digunakan sebagai imunoterapi alternatif untuk memerangi jangkitan kuman tuberkulosis terpendam di masa depan.

**DEVELOPMENT OF HSPX VACCINE AGAINST LATENT
TUBERCULOSIS USING ADJUVANT-DEPENDENT T-HELPER
ALTERNATING PETPIDE STRATEGY**

ABSTRACT

Cellular immunity is a critical factor to be considered in developing an effective vaccine against *Mycobacterium tuberculosis*. Crosstalk between CD4⁺ and CD8⁺ T-lymphocytes play central roles in initiating cytotoxic killing to the infected cells, contributing to a complete clearance of intracellular tuberculosis bacilli *Mycobacterium tuberculosis* during infection. Based on these principles, our study proposed a novel alternating MHC-restricted peptide vaccination strategy to improve the rise of antigen-specific CD8⁺ T-cell response against alpha-crystalline heat-shock protein (HspX). Combined adjuvant for synergistic stimulation of cellular immunity (CASAC) adjuvant was included in the vaccine regimen to improve their immunogenicity against HspX antigen. Results indicated that recombinant HspX protein was proven to be immunogenic in C57BL/6 mice, showing an improved antigen-specific IgG₁ and IgG_{2a} antibody secretion and memory CD8⁺ T-cell immunity under stimulation of CASAC adjuvant. Such potent adjuvant enhanced the level of IFN- γ and TNF- α secretion with reduced IL-10 suppression, demonstrating a predominant Th1-mediated immunity against HspX antigen. In peptide vaccination study, C57BL/6 mice were primed with rHspX protein and consecutively stimulated with subunit vaccines formulated with MHC-I/MHC-II peptides and CASAC adjuvant. Our novel alternating peptide vaccination significantly stimulated a substantial level of Th1-mediated CD8⁺ T-cell response against HspX antigen, represented with elevated secretion of IFN- γ and IL-2 cytokines. It also generated a